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Hyperglycemia, in the absence of type 1 or 2 diabetes, is an independent risk factor for
cardiovascular disease.We have previously demonstrated a central role for mannose bind-
ing lectin (MBL)-mediated cardiac dysfunction in acute hyperglycemic mice. In this study,
we applied whole-genome microarray data analysis to investigate MBL’s role in system-
atic gene expression changes. The data predict possible intracellular events taking place
in multiple cellular compartments such as enhanced insulin signaling pathway sensitiv-
ity, promoted mitochondrial respiratory function, improved cellular energy expenditure and
protein quality control, improved cytoskeleton structure, and facilitated intracellular trafﬁck-
ing, all of which may contribute to the organismal health of MBL null mice against acute
hyperglycemia. Our data show a tight association between gene expression proﬁle and tis-
sue function which might be a very useful tool in predicting cellular targets and regulatory
networks connected with in vivo observations, providing clues for further mechanistic
studies.
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INTRODUCTION
Diabetes mellitus has emerged as a major threat to worldwide
health (Bojadzievski and Gabbay, 2011). Cardiovascular compli-
cations associated with hyperglycemia include cardiomyopathy
and vasculopathy (Van Gaal et al., 2006). The pathophysiology of
diabetic cardiomyopathy is likely multifactorial, with experimen-
tal evidence pointing to involvement of the rennin–angiotensin
system (RAS), reactive oxygen species (ROS), and advanced gly-
cosylation end (AGE) products and their receptors, which activate
a number of secondary messenger pathways leading to activa-
tion and recruitment of inﬂammatory cells (Giacco and Brownlee,
2010). These molecular and cellular events culminate in the devel-
opment of cardiac ﬁbrosis, hypertrophy, and vascular dysfunction
leading to cardiac dysfunction and enhanced injury. A connec-
tion between hyperglycemia-induced vasculopathy and the innate
immune system, particularly mannose binding lectin (MBL), was
demonstrated in diabetic patients (Hansen et al., 2004; Hovind
et al., 2005; Fortpied et al., 2010).
Acute hyperglycemia, reported in many critical care settings,
was originally regarded as non-problematic and potentially ben-
eﬁcial, by ensuring an adequate glucose supply to the brain
and immune system. However, hyperglycemia, in the absence
of type 1 or 2 diabetes mellitus, is an independent risk fac-
tor for cardiovascular disease (Davidson and Parkin, 2009).
Hyperglycemia-induced injuries phenotypically mirror those
of pressure-overloaded cardiac hypertrophy, and hyperglycemic
patients have the same cardiovascular risk as patients who have
had a myocardial infarction (Ceriello, 2005). Acute hyperglycemic
disturbances are potent predictors of mortality in patients without
previously diagnosed diabetes mellitus (Gustafsson et al., 2007).
We have established a short term (14-day) hyperglycemic
mouse model that yields many of the features of hyperglycemia-
induced cardiomyopathy and enhanced injury following myocar-
dial ischemia and reperfusion (Busche et al., 2008). As com-
pared to MBL null mice, hyperglycemic WT mice presented
with signiﬁcantly decreased left ventricular ejection fractions and
increased serum troponin I levels. Echocardiographic measure-
ments demonstrated signs of dilative cardiomyopathy, whereas
heart:body weight ratios suggested hypertrophic cardiac remodel-
ing after 2 weeks of hyperglycemia. Immunohistochemical analysis
of cardiac progenitor cells showed signiﬁcantly lower numbers
in diabetic WT hearts (Busche et al., 2008). Our followup study
further revealed that short term hyperglycemia (4 and 14 day),
independent of oxidative stress or insulin levels, led to dilated
cardiomyopathy with signiﬁcantly increased short and long axis
area measurements during systole and diastole in hyperglycemic
WTmice compared toMBLnullmice. The EC50 for acetylcholine-
induced relaxation of mesenteric arterioles in WT mice following
4 days of hyperglycemia demonstrated a signiﬁcant loss of nitric
oxide-mediated relaxation. The hyperglycemic WT vasculopathy
phenotype could be restored in the MBL null mice by addition
of recombinant MBL during the hyperglycemic period. Myocar-
dial histochemistry and western blots revealed a signiﬁcant inﬂux
of macrophages, altered morphology, and increased elastin and
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collagen deposition in hyperglycemic WT hearts. Serum TGF-β1
levels were signiﬁcantly lower in hyperglycemic MBL null com-
pared to WT mice, suggesting decreased pro-ﬁbrotic signaling
(Pavlov et al., 2012).
It is likely that the molecular mechanisms involved in the
hyperglycemia-induced cardiomyopathy and vasculopathy differ-
ences observed in the WT and MBL null genotypes are multifac-
torial. In the present study, we explored the whole-genome gene
expression proﬁles of left ventricular transcripts from WT and
MBL null mice following acute hyperglycemia in order to pro-
vide a basis for future study and investigation on the molecular
mechanisms involved in this model. We used high-throughput
whole-genome microarray scans as well as the database for anno-
tation, visualization, and integrated discovery (DAVID) analysis
tool to compare the gene transcriptional variances from 12murine
left ventricle samples (File Sa0 in Supplementary Material). The
purpose of this study was to establish the intrinsic relationship
between gene transcriptional changes and animal organ functional
outcomes. The predicted cellular targets and regulatory networks
connecting MBL with hyperglycemia-induced vasculopathy and
cardiomyopathy presented in this studywill facilitate futuremech-
anistic studies in this model. We have already used these data
to investigate successfully several molecular mechanisms involved
and several additional manuscripts are in preparation. We believe
that this study demonstrates a successful way to use microarray
data to predict preclinical endpoints (MAQC-Consortium, 2010).
MATERIALS AND METHODS
AGENTS AND CHEMICALS
Streptozotocin (STZ) was purchased (Sigma-Aldrich; St. Louis,
MO, USA). Citrated saline was purchased from ALEXIS (Lausen,
Switzerland).
ANIMALS
Mannose binding lectin null mice were developed by our collab-
orators and now have been deposited to The Jackson Laboratory
(Takahashi et al., 2002; Shi et al., 2004). Male C57BL/6 (WT) mice
(8–12weeks old,Taconic Farms)were used as background controls
forMBL nullmice as directed by the online instruction1. TheMBL
null line was backcrossed to greater than 96% C57BL/6 (Moller-
Kristensen et al., 2007). The following groups were studied: (1)
WT and MBL null mice following 4-days of hyperglycemia and
(2) WT and MBL null mice following 14-days of hyperglycemia
(n = 3/group). Mice were housed four per cage and had unlimited
access to water and standard mouse chow. All procedures were
reviewed and conducted according to the Institute’s Animal Care
and Use Committee. All experiments were performed under the
standards and principles set forth in the Guide for Care and Use
of Laboratory Animals, published by National Institute of Health
(NIH Publication No. 85-23, Revised 1996).
HYPERGLYCEMIA INDUCTION
Hyperglycemia was induced by a single injection of freshly pre-
pared STZ solution (200mg/kg body weight, i.p. in citrated saline,
1http://jaxmice.jax.org/strain/006122.html
pH 4.2). Urinary glucose was tested on the fourth day following
STZ injection and once more before the mice euthanized for
tissue sampling and freezing. Mice with urinary glucose levels
greater than 500mg/dl (measuredwithGlucostix byDiastix,Bayer,
Elkhart, IN, USA) in both tests were considered hyperglycemic.
Control mice were injected with citrated saline. Sera insulin and
glucose levels in thismodel have beenpublishedpreviously (Pavlov
et al., 2012).
GENOME-WIDE EXPRESSION PROFILING
Left ventricle free walls of mice were sent to GenUs BioSystems2
for microarray processing. Brieﬂy, RNA was extracted and puri-
ﬁed using Ribopure (Ambion) RNA isolation. The quality of total
RNA was assessed using an Agilent Bioanalyzer. After ﬁrst and
second strand cDNA preparation, cRNA target was acquired from
the DNA template and veriﬁed on the Bioanalyzer. cRNAwas then
fragmented to uniform size and hybridized to Agilent Mouse GE
4K× 44K v2 arrays. Slides were washed and scanned on an Agi-
lent G2565 Microarray Scanner. Data were analyzed with Agilent
Feature Extraction and GeneSpring GX v7.3.1 software packages.
MICROARRAY DATA ANALYSIS
The original microarray probe intensity data are listed (File Sa0
in Supplementary Material). Only genes differently expressed
(MBL null vs. WT, t -test, p< 0.05) were uploaded with their
Entrez Gene ID to DAVID3. Four or fourteen-day hyperglycemic
groups, up-regulated (MBL null/WT> 1) or down-regulated
(MBL null/WT< 1) genes were analyzed separately following the
published protocol for DAVID (Huang et al., 2009). Gene func-
tional classiﬁcationwas employed to explore and view functionally
related genes together, as a unit, to concentrate on the larger bio-
logical network rather than at the level of individual genes. The
mouse whole-genome was set as the population background in
enrichment analysis. We used the highest classiﬁcation stringency
to generate less functional gene groups with more tightly associ-
ated genes in each group. Only groups with an enrichment score
greater than 2 (which means statistical signiﬁcance p< 0.01 for
the gene enrichment) were counted. The physiological meaning
of clustered genes was extracted by analyzing the biological func-
tions of those gene families. The gene summary of individual
genes (by clicking the gene name) as well as gene ontology terms
(by clicking the red “T” on the right of enrichment score) was
also explored to assist in understanding these highly organized
biologically meaningful modules.
STATISTICAL ANALYSIS
Microarray probe intensity comparisons between WT and MBL
null groups were made using Student’s t -test. The differences were
considered signiﬁcant at p< 0.05.
RESULTS
Differentially expressed genes (File Sa1–4 in SupplementaryMate-
rial) were functionally classiﬁed into groups by DAVID (File
Sb1–4 in Supplementary Material). Those gene clusters as well
as afﬁliated gene families were also categorized in Tables 1–4.
2http://www.genusbiosystems.com
3http://david.abcc.ncifcrf.gov
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Table 1 | Gene families of up-regulated genes in 4-day hyperglycemic MBL null mice compared toWT control.
Category DAVID gene group
number
Gene families
Miscellaneous purine
nucleotide binding protein
1, 15 Ras, Rab, Rho, Arf, (IAN; GTPBP1) GTP-binding protein, GBP, RasD, RHD3, SRP recep-
tor beta subunit, GTP-binding elongation factor, eIF-2-beta/eIF-5, GTP1/OBG, GTR/RAG,
GPN-loop GTPase, immunity-related GTPase, interferon inducible GTPase
2, 10, 11 ATP-dependent AMP-binding enzyme,TCP-1 chaperonin, ABC transporter, ADCK protein
kinase, AAA ATPase, NLRP, DEAD box helicase, SNF2/RAD54 helicase, clpA/clpB, heat
shock protein 90, kinesin-like protein, actin
5, 6 FAST kinase, Ser/Thr protein kinase, APG1/unc-51/ULK1 kinase, uridine kinase, CMGC
kinase, STE kinase, CAMK kinase, AGC kinase, Tyr protein kinase, CK1 kinase, RIO-type
kinase, TKL kinase, ADCK kinase, Alpha-type protein kinase
Ribosomal biogenesis and
RNA processing
4, 17, 18 RRM CPSF6/7, splicing factor SR, EBP2, RRP1, ribosomal protein (L24e; S8e), SDA1,
BXDC2/BRX1, KRR1, SEN54, NOP14
Peptidase and
ubiquitin-dependent
proteolytic pathway
3, 7, 8, 14, 19, 21, 27 Ubiquitin-conjugating enzyme, ubiquitin-activating E1, ubiquitin ligase, DDA1, DET1,
Tdpoz, KCMF1, RBR, RNF181, SPSB, fem-1, cytidine and deoxycytidylate deaminase,
deoxycytidylate deaminase, phosphotriesterase, UPF0054, glyoxalase II, peptidase (C12;
C19; C48), peptidase (M16; M18; M22; M48)
Aminoacyl-tRNA synthetase 9 Class-I aminoacyl-tRNA synthetase, class-II aminoacyl-tRNA synthetase, phenylalanyl-
tRNA synthetase beta chain
Transcription regulator 12, 20, 22, 24, 28 EAF7, ESF1, mediator complex subunit (20; 24), ELL/occludin, THAP1, TFB4, TFIIB,
GTF2H2, TRIM/RBCC, ZPR1, muscleblind, DEF8, RNF (10; 121; 181), ZC3H14, VPS8,
nuclear hormone receptor, (krueppel; AEBP2/jing; Ikaros) C2H2-type zinc-ﬁnger protein,
SAYP, bZIP, TAF3, peptidase M50A,YY transcription factor, ETS
Cytoskeleton 13 SMEK, PPP4R2, GCP
WD repeats 16 WD repeat (EMAP; CIA1; SMU1; striatin; SWD2; SEC31; BCAS3; G protein beta; ATG16;
WDR24; L2GL; PWP2; TAF5)
Intracellular trafﬁcking 23, 25, 26 COG (1; 2; 4; 6; 7), XPO2/CSE1, importin (alpha; beta), DHHC palmitoyltransferase,
MPPE1
Tetratricopeptide repeats 29 TTC (9; 27; 38), IFIT
Mitochondrial membrane 30 Mitochondrial carrier, tango11, SAM50/omp85, COX15/ctaA
Differently expressed genes (MBL null vs. WT, t-test, p<0.05, n=3) were uploaded with their Entrez Gene ID to DAVID for functional classiﬁcation. Gene family
names are summarized for each clustered gene group.
Table 2 | Gene families of down-regulated genes in 4-day hyperglycemic MBL null mice compared toWT control.
Category DAVID gene
group number
Gene families
Ribosomal biogenesis
and RNA processing
1, 3, 4 Ribosomal protein (S7e; L15P; S24e; L44e; S10P; L23P; L10e; L30e; L32e; L31e; S4e; L30P; S25e; L18P;
L12P; L13P; S3Ae; L13e; S12P; L14e; L6e; L10P; L6P; L34e; L22e; L4P; L1P; L21e; L22P; S19P; L5P;
S12e; L35Ae, S8e), CWF11, splicing factor SR, snRNP core protein, RRM U1 A/B, U2 small nuclear
ribonucleoprotein A, snRNP Sm, rRNA adenine N (6)-methyltransferase, nucleoplasmin
Transcription regulator 2, 5 TAP26,TORC, LEO1, CBF/MAK21, GCF, HEXIM, muscleblind, ZC3H15/TMA46, Luc7, unkempt,TRIM/RBCC
Cytoskeleton 6, 8 Intermediate ﬁlament, tubulin
Nucleosome 7 Histone (H2A; H3)
Differently expressed genes (MBL null vs. WT, t-test, p<0.05, n=3) were uploaded with their Entrez Gene ID to DAVID for functional classiﬁcation. Gene family
names are summarized for each clustered gene group.
HIGHER EXPRESSION OF DOWNSTREAM EFFECTORS IN
HYPERGLYCEMIC MBL NULL MICE MAY SENSITIZE INSULIN
SIGNALING PATHWAYS
STZ selectively kills insulin-secreting β cells and the subsequent
lack of insulin leads to increased blood and urinary glucose.
Insulin has important cardiac actions. Diminished or resistant
insulin signaling results in cardiomyopathy and vasculopathy,with
complications including non-ischemic heart failure, which is a
consequence of lipotoxicity, sympathetic up-regulation, inﬂam-
mation, oxidative stress, and ﬁbrosis (Witteles and Fowler, 2008);
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Table 3 | Gene families of up-regulated genes in 14-day hyperglycemic MBL null mice compared toWT control.
Category DAVID gene
group number
Gene families
Mitochondrion ribosome 1 Mitochondrial ribosomal protein (S30/L37; L4P; L41; S7P; S5P; L30P; S25/L51; L47em; L28e; S9P;
L35P; L49em; L12P; L24P; L21e; L15e; L34P; L15P; L36P; S14P; S11P; L10P; L46; L31e; S8P; S12P;
S2P; L14P; L28P)
Mitochondrial membrane 2, 7 Mitochondrial carrier, complex I NDUFB5 subunit, Tom (5; 22; 40), Tim (17; 22; 23), complex I
LYR, SURF1, SAM50/omp85, cytochrome c oxidase VIIa, eukaryotic mitochondrial porin, small Tim,
metaxin, methyltransferase, AAA ATPase
Aminoacyl-tRNA synthetase 3 Class-I aminoacyl-tRNA synthetase, class-II aminoacyl-tRNA synthetase, gatB/gatE
Miscellaneous purine
nucleotide binding protein
4, 8 TCP-1 chaperonin, ABC transporter, heat shock protein 70, Mrp/NBP35, argK, recA, ORC(4; 5),
Mrp/NBP35, gluconokinase gntK/gntV
5 Arf, Ras, Rab, GBP, transferase hexapeptide repeat, GPN-loop GTPase, RHD3, (era/mnmE; IAN;
MMR1/HSR1) GTP-binding protein, Rho, interferon inducible GTPase, GTP1/OBG
14 Ser/Thr protein kinase, CAMK kinase,Tyr protein kinase,TKL kinase, STE kinase, CMGC kinase, NEK
kinase, CK1 kinase, AGC kinase
Peptidase and
ubiquitin-dependent
proteolytic pathway
6, 15, 17 Ubiquitin-conjugating enzyme, peptidase (M3; M16; M22; M48), peptidase (T1A; T1B)
Ribosomal biogenesis and
RNA processing
9, 16 snRNP SmB/SmN, RRM HNRPC, cyclophilin-type PPIase, RRM U1 A/B, snRNP Sm protein, NEP1,
AROS, RRP1, RNAse PH, EBP2, BXDC2/BRX1, ribosomal protein (L24e, S8e)
WD repeats 10 WD repeat (THOC6; SEC13; CIA1; SMU1; EMAP; SWD2; BCAS3; SEC31; AIP1; MORG1; G protein
beta), eIF-3 subunit I, dynein intermediate chain
Intracellular trafﬁcking 11 Sorting nexin
Cytoskeleton 12 Tubulin
Tetratricopeptide repeats 13 TMTC, TTC27, GPSM, FAM10, IFIT
Nucleosome 18 Histone (H1/H5; H2A), NAP
Differently expressed genes (MBL null vs. WT, t-test, p<0.05, n=3) were uploaded with their Entrez Gene ID to DAVID for functional classiﬁcation. Gene family
names are summarized for each clustered gene group.
Table 4 | Gene families of down-regulated genes in 14-day hyperglycemic MBL null mice compared toWT control.
Category DAVID gene
group number
Gene families
Transcription regulator 1, 3, 5, 10, 13 TAP26, TORC, LEO1, NELF-A, NELF-B, CBF/MAK21, HEXIM, ZC3H15/TMA46, muscleblind, Luc7,
unkempt, bZIP, (krueppel; Sp1; snail; teashirt; GLI; DZIP) C2H2-type zinc-ﬁnger protein,TCF25, BCOR,
ETS, nuclear hormone receptor,
Ribosomal biogenesis and
RNA processing
2, 4, 6, 8 Ribosomal protein (S7e; L15P; S24e; L23P; L30e; L32e; L31e; S25e; L18P; L13P; S3Ae; L15e; L13e;
L10P; L6e; L6P; L4P; L21e; L22P; L5P; S12e; S8e), RRS1, UTP6, RRP40, SDA1,MPP10, UTP23/FCF1,
RNA 3′-terminal cyclase, nucleoplasmin, rRNA adenine N(6)-methyltransferase, U2 small nuclear
ribonucleoprotein A, CWF11, SLT11, SNU66/SART1, cyclophilin-type PPIase, gemin-2, splicing factor
SR, SMN
Peptidase and
ubiquitin-dependent
proteolytic pathway
7, 11 UBR (1; 4), SH3RF, RBR, peptidase (C19; T1A)
Intracellular trafﬁcking 9 Arf GTPase activating protein
Miscellaneous purine
nucleotide binding protein
12 SNF2/RAD54 helicase, DEAD box helicase
WD repeats 14 WD repeat (mio; TAF5; HIR1; PLAP; GAD-1)
Cytoskeleton 15 SFI1, GCP
Differently expressed genes (MBL null vs. WT, t-test, p<0.05, n=3) were uploaded with their Entrez Gene ID to DAVID for functional classiﬁcation. Gene family
names are summarized for each clustered gene group.
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as well as hypertension, coronary heart disease, and atheroscle-
rosis which are all characterized by endothelial cell dysfunction
(Muniyappa et al., 2007).
Insulin signaling transduction is initiated by phosphorylation
of the insulin receptor (Tyr protein kinase family; White, 2002).
The insulin-growth factor-1 receptor (Tyr protein kinase family)
can also be activated by insulin. As a consequence, two main
signaling pathways are activated: phosphatidylinositol 3-kinase
(PI3K)–AKT/protein kinase B (AGC Ser/Thr protein kinase fam-
ily) pathway, which is responsible for a majority of the metabolic
actions of insulin, and the Ras–mitogen-activated protein kinase
(MAPK, CMGC Ser/Thr protein kinase family) pathway which
regulates cell growth and differentiation (Taniguchi et al., 2006).
PI3K activates critical regulators of insulin signaling by cat-
alyzing the formation of the lipid second messenger, PIP3, in the
cell. Proteins with pleckstrin homology (PH) domains bind PIP3,
which allows for their activation (Taniguchi et al., 2006). These
proteins belong to theAGC Ser/Thr protein kinase, Tyr kinase, and
Rho family. Glycogen synthase kinase-3 (CMGC Ser/Thr protein
kinase family) is a target of AKT which regulates glycogen synthe-
sis. AKT also regulates glucose uptake by triggering the activation
of Rab small GTPases (Rab family) which involves cytoskeletal
re-organization that is required for translocation of the glucose
transporter (Taniguchi et al., 2006). AKT also effectively activates
themTOR pathway and regulates protein synthesis by phosphory-
lating the p70 ribosomal protein S6 kinase (AGC Ser/Thr protein
kinase family). Atypical protein kinase C (aPKC, AGC Ser/Thr
protein kinase family) is another downstream effector of PI3K
and plays a role in glucose homeostasis (Taniguchi et al., 2006).
Activation of MAPK triggers the activation of the small GTPase
Ras (Ras family) and a kinase cascade includingMEK1 and 2 (STE
Ser/Thr protein kinase family), ERKs (CMGC Ser/Thr protein
kinase family), p90RSK (AGC Ser/Thr protein kinase family), and
a transcription factor ELK1 (ETS family). Small GTPase Rac and
CDC42 (Rho family) have also been implicated in insulin’s action
by triggering downstream effectors involved in the rearrangement
of the actin cytoskeleton (Taniguchi et al., 2006).
All gene families mentioned above can be found in Tables 1
and 3, and are signiﬁcantly up-regulated in 4 and 14-day hyper-
glycemic MBL null mice compared to the respective WT group.
Robustly expressed members of these gene families may act syn-
ergistically to sensitize the insulin signaling pathway in MBL null
mice.
CARDIAC MITOCHONDRIAL FUNCTIONS ARE PRESERVED IN
HYPERGLYCEMIC MBL NULL MICE
Mitochondria are the primary energy source fueling the contrac-
tile apparatus of the heart and are therefore key players in the
progression of heart failure (Rosca and Hoppel, 2010). Damage to
the cardiovascular endothelium is one of the ﬁrst steps leading to
heart disease, detectable even before structural changes to the ves-
sel wall are apparent, as we recently demonstrated (Pavlov et al.,
2012). Disruption of mitochondrial activities affects endothelial
function and conceivably contributes to heart disease (Davidson,
2010).
We found scores of mitochondrial functional genes up-
regulated in 4 and 14-day hyperglycemic MBL null mice (Tables 1
and 3) compared to their WT counterparts in response to
hyperglycemic stress.
A down-regulation of the entire pathway of mitochondrial
biogenesis appears in heart failure (Rosca and Hoppel, 2010).
Mitochondrial biogenesis is a complex and dynamic process that
regulates and determines the content and composition of mito-
chondria including mtDNA replication, nuclear-encoded pro-
tein synthesis, and incorporation into mitochondrial membranes
and matrix (Bugger and Abel, 2010). Division of pre-existent
organelles is dependent on mitochondrial ﬁssion, which also
requires protein biosynthesis. In hyperglycemic MBL null mice,
dozens of up-regulated mitochondrial ribosomal protein families
were observed, including those of the Tango11 family, which may
represent partially preserved mitochondrial biogenesis capability.
Members of SAM50/omp85, Tom, Tim, small Tim, and metaxin
families work as chaperones in guiding protein incorporation into
mitochondrial membranes.
The myocardium depends on continuous oxidation of energy
metabolic substrates for sufﬁcient ATP generation to maintain
contractile function. The myocardium uses even more energy
under hyperglycemic conditions. The mitochondrial respiratory
chain is the principal source of cellular ROS,which can lead to cel-
lular damage andmayultimately result in reducedATPproduction
and impair contractility (Bugger andAbel, 2010). The primary fac-
tor governing mitochondrial ROS generation is the redox state of
the respiratory chain. Abundant mitochondrial respiratory chain
complexes help overcome energy-generating deﬁciencies, thereby
maintaining a positive redox state with diminished ROS pro-
duction. Up-regulated gene families in hyperglycemic MBL null
mice which are components of themitochondria respiratory chain
include: complex INDUFB5 subunit, complex I LYR,methyltrans-
ferase, AAA ATPase, cytochrome c oxidase VIIa, COX15/ctaA, and
SURF1. The mitochondrial carrier and porin families are groups
of proteins which import or export speciﬁcmolecules acrossmito-
chondrial membranes. Facilitated solute trafﬁcking/metabolites
exchange plays a vital role in maintaining normal mitochondrial
function (Nury et al., 2006).
ADVANTAGEOUS TRANSCRIPTIONAL AND TRANSLATIONAL ADAPTION
IN HYPERGLYCEMIC MBL NULL MICE
The myocardium is a high energy-consuming organ requiring a
constant energy supply to maintain intracellular ATP levels essen-
tial for the uninterrupted myocardial contraction/relaxation cycle
(Bertrand et al., 2008). It is reasonable that protein synthesis,
which also requires high energy supply, would be suppressed in
the insulin deﬁcient state in favor of normal cardiac physiological
function (Bertrand et al., 2008).
We found evidence that overall left ventricular protein synthe-
sis is decreased more in hyperglycemic MBL null mice compared
WT counterparts, likely to further lower energy usage during
hyperglycemia. Furthermore, synthesis of speciﬁc proteins might
be differentially regulated by transcriptional regulators in order
to maintain a more effective defense against hyperglycemia. The
ribosome is responsible for protein synthesis in all cells, whose
large and small subunits consist of ribosomal RNA and proteins
(Schmeing andRamakrishnan,2009).Weobserved anoverwhelm-
ing down-regulation of ribosomal protein families in both 4 and
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14-day hyperglycemic MBL null mice (Table 2, gene group 1 and
Table 4, gene group 2), indicating ribosomal biogenesis may be
greatly suppressed, leading to decreased protein synthesis. How-
ever, synthesis of speciﬁc proteins may remain active, as members
of aminoacyl-tRNA synthetase families were increased (Table 1,
gene group 9 and Table 3, gene group 3) as well as some mRNA
translation activators, the GTP-binding elongation factor family
and eIF-2-beta/eIF-5 family (Table 1, gene group 1). In addition,
elevated DNA/RNA helicase (Table 1, gene group 10) and reduced
histone expression (Table 2, gene group 7) were suggestive of an
active transcription/translation process.
It is likely that the speciﬁcity of those proteins still being syn-
thesized is determined by transcription regulators. Unfortunately,
we were not able to fully elucidate these regulators because of the
complex interactions of these gene families. Therefore, we only
extracted partial functional features of those genes and analyzed
their physiological implications.
Selectively enhanced gene families include: promoting tran-
scription activities (Table 1, gene groups 12 and 20), cell growth,
division and differentiation (Table 1, gene groups 22, 24, and 28),
and hormone receptors (Table 1, gene group 24). These gene fam-
ilies were only regulated in early (4-day) but not later (14-day)
hyperglycemic stages. Therefore, they are likely offering initial
emergent protection to cells against acute hyperglycemia.
Selectively inhibited gene families in 4 and 14-day samples
include certain transcription suppressors (Table 2, gene group 2;
Table 4, gene groups 1, 10, and 13); cell growth inhibition, terminal
differentiation proteins and DNA damage sensors (Table 2, gene
group 5; Table 4, gene groups 3 and 10), and hormone receptors
(Table 4, gene groups 5 and 13). Generally, these changes reﬂect
sustained gene transcription, cell growth, and prevention of apop-
tosis. However, in 14-day hyperglycemia samples, down-regulated
hormone receptors, and DNA helicase expression (Table 4, gene
group 12) plus restored histone expression (Table 3, gene group
18) indicate negative feedback loops may be observed.
INDUCED UBIQUITIN-DEPENDENT PROTEOLYTIC CASCADE HELPS
CARDIAC CELLS SURVIVE INITIAL HYPERGLYCEMIC STRESS IN MBL
NULL MICE
Gene families associated with the ubiquitin-dependent proteolytic
pathway were overwhelmingly expressed at higher levels in 4-
day hyperglycemic MBL null murine left ventricles (Table 1, gene
groups 3, 7, 8, 14, 19, 21, and 27). Members of these gene families
are involved in various steps of ubiquitin-dependent proteolytic
cascades. This increased expression, however, was not obvious in
the hearts of 14-day hyperglycemic mice. Therefore, this may be
another rescue measure for cardiac cells to survive initial acute
hyperglycemia in MBL null mice.
Hyperglycemia induces protein misfolding and results in
altered organ function or failure (Herczenik and Gebbink, 2008).
Cell protein quality control functions to minimize the produc-
tion of abnormal proteins, remove abnormal proteins, or prevent
abnormal proteins from damaging the cell. The myocardium is
arguably one of the most stressed organs in the body, therefore,
protein quality control is a vital cellular process for cardiomyocyte
and cardiovascular endothelial cell functions (Stangl and Stangl,
2010; Su andWang, 2010).
It is noteworthy that the role of the ubiquitin proteasome sys-
tem in protein quality control has expanded with new studies
delineating its cross-talkwith the process of autophagy.Autophagy
also works as a cellular housekeeper and plays a vital role to
eliminate defective proteins and organelles, prevent abnormal pro-
tein aggregate accumulation, and remove intracellular pathogens
(Levine and Kroemer, 2008; Willis et al., 2010).
CARDIAC CONTRACTILE DYSFUNCTION MAY BE REVERSED BY
ADVANTAGEOUS CYTOSKELETON ALTERATIONS IN MBL NULL MICE
The cytoskeleton is a complex network of ﬁlaments and tubules
which transmit mechanical and chemical stimuli within and
between cells. The cytoskeleton contributes to cell stability by
anchoring subcellular structures such as mitochondria, Golgi
apparatus, nuclei, and myoﬁbrils (Hein et al., 2000).
Vascular endothelial cells are vulnerable to glucose-derived
oxoaldehydes through the formation of AGEs, which induce
cytoskeleton rearrangement and endothelial barrier dysfunction
(Sliman et al., 2010). Heart failure is also characterized by
cytoskeletal alterations resulting in reduced ventricular function.
Cytoskeletal abnormalities rather than myoﬁlament changes are
responsible for cellular contractile dysfunction (Hein et al., 2000).
The absence of changes in mRNA levels of actin (actin fam-
ily) but the abundance of tubulin (tubulin family) mRNA and
microtubules were observed in pigs with heart failure (Hein et al.,
2000). Meanwhile, contractile dysfunction and increased micro-
tubules/cytoskeletal stiffness in failing hearts can be reversed by
reducing the rate of tubulin polymerization (Hein et al., 2000). A
progressive increase of desmin (intermediate ﬁlament family) was
observed also during the transition from hypertrophy to failure in
guinea pig hearts after aortic banding (Hein et al., 2000).
The expression of PPP4R2 and SMEK (PPP4R2 and SMEK
families) leads to microtubule disruption and dysfunction (Liu
et al., 2007; Martin-Granados et al., 2008). SFI1 (SFI1 family) is
an essential gene required for spindle pole body duplication and
bipolar spindle assembly (Anderson et al., 2007).
We observed in the early stage of hyperglycemia (4-day), actin
gene family (with a main role in intracellular trafﬁcking) expres-
sion levels are increased (Table 1) while intermediate ﬁlament and
tubulin gene family expression levels are suppressed (Table 2).
Therefore, microtubule depolymerization would be enhanced
in the hyperglycemic MBL null mouse. In the later stages of
hyperglycemia (14-day), despite the restored tubulin expression
(Table 3), a down-regulation of SFI1 family genes (Table 4), which
assists in anchoring tubulin, still puts microtubule polymeriza-
tion under strict control. All the changes mentioned above would
contribute to beneﬁcial cytoskeleton rearrangements in MBL null
mouse hearts in response to acute hyperglycemic stress compared
to the WT genotype.
POSSIBLE FACILITATED INTRACELLULAR TRAFFICKING HELPS
MAINTAIN NORMAL PHYSIOLOGICAL MYOCARDIAL FUNCTION IN
HYPERGLYCEMIC MBL NULL MICE
The Golgi apparatus is a hub for membrane-trafﬁcking and plays
a key role in processing and secretion of glycoproteins, glycolipids,
and proteoglycans. COG families (Table 1) are among the list of
up-regulated gene families. The COG complex is preferentially
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localized to the cis/medial cisternae of the Golgi apparatus and
is involved in Golgi membrane trafﬁc (Shestakova et al., 2006).
The DHHC palmitoyltransferase family (Table 1) is responsible
for adding palmitates to cytoplasmic proteins participating in the
process of protein trafﬁcking between organelles and in the segre-
gation/clustering of proteins inmembrane compartments (Linder
and Deschenes, 2007). TheMPPE1 family (Table 1) is required for
transport of GPI-anchor proteins from the endoplasmic reticulum
to the Golgi (Fujita et al., 2009). The endosomal system functions
to sort and deliver internalized proteins to appropriate subcel-
lular destinations. The Sorting nexin family (Table 3) regulates
endosomal sorting of internalized proteins through modulating
endosomal-to-lysosomal sorting (Carlton et al., 2004). Both ele-
vated Arf GTPase (Tables 1 and 3) or attenuated Arf GTPase
activating protein family (Table 4) expression may help main-
tain Arf GTPase activity which is essential for the recruitment of
coat protein complex I and clathrin coat complexes needed for the
generation of transport vesicles (Benjamin et al., 2011).
During interphase, thousands of nuclear proteins and RNAs
cross the nuclear envelope tomove from the cellular compartment
in which they are synthesized to their ﬁnal destination. Trans-
port occurs through nuclear pore complexes and is mediated by
nucleocytoplasmic transport receptors. Cse1 (XPO2/CSE1 family,
Table 1) is the exportin that mediates the recycling of importin α
(importin families, Table 1; Cook et al., 2005). Increased expres-
sion of these gene family members may indicate a facilitated
nuclear transport in theMBLnull genotype during hyperglycemia.
The ABC transporter gene family is among those up-regulated
genes in both 4 and 14-day hyperglycemicMBLnullmice (Tables 1
and 3). ABC transporters are transmembrane proteins that utilize
ATP hydrolysis to translocate a wide variety of substrates across
extra- and intracellular membranes, including amino acids, sug-
ars, ions, glycans, peptides, proteins, lipids, and sterols (Dean et al.,
2001; Couture et al., 2006). Expression of ABC transporters in
the heart is associated with regulation of normal physiological
function as well as protection and detoxiﬁcation of the organism
(Couture et al., 2006, 2007).
DISCUSSION
Poor glycemic control is associated with microvascular and
macrovascular disease, yet a link with cardiovascular events is less
clear. Previous studies from our group support an important role
for MBL and the lectin complement pathway in mediating the
cardiomyopathy and vasculopathy associated with acute hyper-
glycemia (Busche et al., 2008; Pavlov et al., 2012). Hyperglycemic
MBL null mice are protected from loss of nitric oxide-mediated
relaxation of arterioles, displayed less myocardial inﬂammation,
and less ventricular remodeling compared to hyperglycemic WT
controls (Pavlov et al., 2012). The purpose of the present study
was to broadly investigate the early and later genetic changes in
the myocardium of hyperglycemic MBL null andWTmice so that
potential molecular mechanisms involved could be investigated
in subsequent studies. This preliminary study will allow us and
others to advance the ﬁeld so that the ﬁndings can be ultimately
translated to the clinic (Collard et al., 2000).
Mouse models using STZ on the C57BL/6 background, which
closely mimic the human disease, are recommended for the
studies of hyperglycemia-induced cardiovascular complications
(Shen and Bornfeldt, 2007). STZ results in acute hyperglycemia
and is cleared from the body within 3 days. Therefore, the short
termhyperglycemia (4–14 days)models rule out any potential car-
diotoxic effects of STZ and enable us to focus on the assessment of
molecular mechanisms in early stage development of cardiovas-
cular pathology as well as further test human treatment solutions
for the prevention of such diseases in the future. We have already
developed an acute hyperglycemia model to investigate the role
of complement and myocardial injury (Busche et al., 2008). In
this study, we were able to provide more evidence that MBL deﬁ-
ciency leads to systematic gene expression changes compared to
WT mice following hyperglycemia. We speculate that possible
intracellular events taking place inmultiple cellular compartments
include enhanced insulin signaling pathway sensitivity, promoted
mitochondrial respiratory function, better cell energy expenditure
and protein quality control, improved cytoskeletal structure, and
facilitated intracellular trafﬁcking. All of these events may con-
tribute to the organismal health of MBL null mice during acute
hyperglycemia.Our data demonstrate an association between gene
expression proﬁle and tissue function which could be a very useful
tool in predicting cellular targets and regulatory networks con-
nected with in vivo observations and generate novel hypotheses
for further mechanistic studies.
High-throughput genomic, proteomic, and bioinformatics
scanning approaches provide signiﬁcant capabilities to study a
large variety of biological mechanisms associated with diseases
(Huang et al., 2009). The DAVID gene functional classiﬁcation
tool classiﬁes large gene lists into functionally related gene groups,
highlights the importance of the discovered gene groups with an
enrichment score, and summarizes the major biological impor-
tance of these gene groups. Our data reveal that all genes in
each gene group were highly arrayed and belonged to one or
multiple gene families. A gene family is a set of several similar
genes, formed by duplication of a single original gene and likely
to have highly similar functions (Demuth et al., 2006). Grouping
genes based on gene families (functional similarity) can system-
atically enhance biological interpretation of large lists of genes
derived from high-throughput studies. Therefore, it provides a
rapid means to organize large lists of genes into functionally
related groups to help unravel the biological content captured by
high-throughput technologies.
The redundancy existing within biological networks means
that modulating a single target might not be sufﬁcient to pro-
duce the desired efﬁcacy in treating complex diseases while, at
the same time, minimizing adverse effects. Therefore, modu-
lating multiple protein targets simultaneously might be a con-
ceivable solution for the design of therapeutic protocols (Mor-
phy and Rankovic, 2007). The combination of high-throughput
microarray scans and DAVID analysis may have potential appli-
cation in the multi-target therapeutic intervention evaluation as
well as the early stage forecast of potential detrimental conse-
quences of treatment. As we advance our current studies exam-
ining the role of MBL in various hyperglycemic models, we
believe these data will drive our studies to testable hypotheses
that could not have been anticipated, if not for this genomic
screen.
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